top of page

HbA1cが低いほどチルゼパチドの減量効果は大きい

Sattar N, Frühbeck G, Andreelli F, et al. Weight Reduction With Tirzepatide Varied Meaningfully by Baseline HbA1c Category in Adults With Overweight or Obesity and Type 2 Diabetes in SURMOUNT-2. Diabetes Care. Published online August 21, 2025. doi:10.2337/dc25-1442

25/8/21

Diabetes Care

介入試験

SURMOUNT-2試験の事後解析(RCT)
過体重or肥満2型DM 938人

チルゼパチド vs プラセボでの体重減少率(%)は、

HbA1c < 7%で -17.7% (-23.0~-12.3)
HbA1c ≧ 7-8%で -13.6% (-15.6~-11.7)
HbA1c ≧ 8%-9%で -11.0% (-13.5~-8.5)
HbA1c ≧ 9%で -9.0%(-13.1~-4.9)

と、HbA1cが低いほど減量効果が有意に大きい結果。

bottom of page